Acino is a Swiss-based pharmaceutical company which was founded in 1836 and which develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms.

Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in 80 fast-growing emerging economies in the Middle East, Africa, Latin America and Asia. In total, Acino operates in 130 countries, employing 790 FTEs and has exclusive access to a 400 person sales force in emerging markets.

On December 12, 2013, Pharma Strategy Partners GmbH, an indirect subsidiary of Nordic Capital Fund VII and its co-investor Avista Capital Partners, successfully completed its public tender offer for Acino Holding AG. The Acino shares have consequently been delisted from the stock exchange.

Key Information

Revenues Icon

Revenues 2017*

EUR 270 million

Employees Icon



Ownership Icon


Nordic Capital Fund VII

Head Office Icon

Head office

Zurich, Switzerland

Investment Icon

Investment date


* Reported